Business Wire

Gurobi 9.5 Delivers Enterprise Features and Even Better Performance

Share

Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, today announced the release of Gurobi Optimizer 9.5. This release provides customers with an even faster compute engine, with impressive performance improvements across all supported problem types.

Gurobi 9.5 also includes new features that make it well suited for enterprise use, including:

  • Seamless Docker Deployments: Run Gurobi in container environments, easily, with the Gurobi Web License Service (WLS).
  • User-Level Management: Manage users and assign permission levels in a centralized location, by integrating Gurobi Compute Server and Cluster Manager with LDAP repositories.
  • Better API Key Management: Label API keys with descriptive information in the Cluster Manager to simplify API key tracking and management.

Customers will discover over a dozen enhancements across the product, such as native support for Apple M1, powerful new heuristics for non-convex quadratic models, norm constraints, deterministic work measures, memory limit parameters, and more user control of IIS computation, as well as improvements to callbacks and tuning.

“I’m confident that our customers will be really pleased with Gurobi 9.5. And happy customers are the foundation upon which our whole business is built,” said Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization.

Gurobi 9.5 also showcases the company’s continued support for Python—the most popular programming language in the world—with an improved Python interface and support for Python 3.10.

“One of the most challenging parts of running a modern business is managing complexity. Every decision you make affects other decisions. With Gurobi Optimizer, you can explore all the possibilities and all the implications—and identify your best course of action, in seconds,” added Dr. Rothberg.

“Even though the Gurobi Optimizer is the fastest mathematical optimizer in the world, we’re not going to rest on our laurels. We will keep pushing to improve and innovate because we’re passionate about mathematical optimization and the difference it makes in solving real-world problems,” said Dr. Tobias Achterberg, Vice President of Research and Development (R&D) at Gurobi Optimization.

The team’s commitment to continual improvement is evident in the performance numbers. Gurobi Optimizer 9.5 has boosted its speeds across the board, including:

  • Primal Simplex: 23% faster overall, 43% faster on hard models
  • Dual Simplex: 20% faster overall, 43% faster on hard models
  • Barrier: 18% faster overall, 56% faster on hard models
  • Concurrent LP: 14% faster overall, 54% faster on hard models
  • MIP: 15% faster overall, 27% faster on hard models
  • Convex MIQP: 30% faster overall, 68% faster on hard models
  • Convex MIQCP: 33% faster overall, 78% faster on hard models
  • Non-Convex MIQCP: 3.0x faster overall, 7.5x faster on hard models

“Our customers rely on us for solving extremely complex challenges. Our technology makes that possible. But our secret sauce is our team of specialists and PhDs, as well as our partner network. These are the people who make Gurobi come to life—working closely with our customers and helping them succeed,” added Dr. Achterberg.

To learn more about Gurobi 9.5, please visit https://www.gurobi.com/9.5.

About Gurobi Optimization

Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.

Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nell-Marie Colman
(540) 952 9719
Gurobi Optimization
colman@gurobi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release

IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye